GNLB, sure:
ragingbull.altavista.com
DNAPRINT GENOMICS (DNAP) Message List Raging Portfolios - Track your stocks here
Quote
Chart
Free E-Mail
Raging DNAP Links
$100 Offer!!
$75 Free Trades Offer
< Previous Respond Next >
By: Chucka $$$$
Reply To: 20592 by T.MAC $$$ Monday, 25 Sep 2000 at 4:03 PM EDT
Post # of 20615
DNA Library Groups must be the parts of the whole I have been following at CYTO and GNLB ( the Merlin Library at Genlabs and the the Genetics High Imput one at the CYTO Subsitary, Progenitcs) RE:
""..
Hi current AT&T WorldNet® Service member!
Thank you for interest in the i495sm Offer, this offer is now available to our AT&T WorldNet® Service members. This page contains instructions on how to download the latest software and how to change your current AT&T WorldNet price plan to take advantage of the i495 Offer. You must complete both of these steps in order to complete the process. PLEASE PRINT OUT THESE INSTRUCTIONS.
Checking your software version:
To switch your price plan to the i495 Offer you must first have AT&T WorldNet client software version 6.0. If you already have a CD Rom check the CD to see if it is version 6.0, anything lower (for example 5.5) will not enable you to switch from a current AT&T WorldNet price plan to the i495 Offer.
I do not have the latest version 6.0 what do I do?
You can go directly to the Price Plan Selection page and follow the directions for the i495 Offer. The instructions will guide you as you download the new 6.0 software. Once you have downloaded version 6.0, you will need to login and authenticate through Member Services to access your Price Plan Selection page. Once there you may select from a number of different price plans including the i495 Offer. To change your price plan see the steps below.
I have the latest version 6.0 what do I do now?
If you have a 6.0 CD-Rom use the CD to update your software, or if you have already downloaded the latest version 6.0 you have completed the first step. Remember downloading version 6.0 does not change your price plan; see the steps below to change your price plan.
To change your price plan:
Select the "Member Services" link on the homepage in the AT&T WorldNet Help section
Select the "Change your Price Plan" link.
Log in and authenticate your account
Select the price plan that fits your needs
Or click on Price Plan to go there now
If you would prefer a CD-Rom with the latest software we would be happy to send you one. Please complete the order form Click here
Which price plan is right for me?
All of our price plans offer the same robust features, including:
• Easy, fast, reliable Internet access nationwide
• 6 e-mail IDs and up to 60 MB of personal Web page space
• Instant Messaging, online communities, chat and newsgroups
• Online customer support
• E-Mail screener to eliminate junk e-mail
• Child safety software
How the i495 Offer differs from other AT&T WorldNet price plans:
AT&T WorldNet Service can offer Internet access at such a great price because advertisers pay AT&T to have their ads displayed to our customers. In addition to the ads you normally see on a Web site, customized ads will appear in a multi-function tool bar on your computer screen while you are online. Our goal is to show you ads that may interest you based on the profile you provide and the Web sites you visit.
Another important difference between our i495 Offer and other price plans is a change to customer support. With the i495 Offer, you will receive free live agent technical support for the first 30 days only. After 30 days, if you have a technical issue and need to speak to a customer care representative, you will be charged on a pay-per-incident basis. However, you are always welcome to take advantage of our online customer support for technical, account maintenance, and billing issues at anytime and without charge. For more information, please go to FAQs on technical support.
i495 Offer includes 150 hours of Internet access per month ($0.99 each additional hour). Telephone access (including local, long distance or 800/888 facility charges) and other charges and taxes may apply. Other terms and conditions apply. Offer subject to change without notice. There are other important differences, so if you'd like to learn more about this offer, please read the i495 Service Agreement, FAQs and
..""
Chucka
cytogen.com
progenics.com
axcellbio.com
and
genelabs.com
and Heat Shock Theraphy Platforms:
antigenics.com
""../
YTO : CYTOGEN CORP (NASDAQ)
All Headlines
AxCell Biosciences Achieves High-Throughput
Automation Goal Cytogen to Expand Its AxCell
Proteomics Subsidiary
PRINCETON, N.J., Sep 12, 2000 /PRNewswire via COMTEX/ -- AxCell Biosciences
Corporation, a wholly owned subsidiary of Cytogen Corporation (Nasdaq: CYTO chart, msgs)
today announced that it has achieved its goal for high-throughput measurement of protein
interactions. AxCell researchers have integrated a series of automated and proprietary,
laboratory procedures involving cloning, robotic sample manipulation, and computerized data
recording into a sustainable, high- throughput commercial process. On a daily basis, scientists
can measure approximately 10,000 protein-protein interactions.
"In just over eight months after moving into our dedicated facility, using our proprietary
high-throughput technology, we have gone from a start-up company to becoming a leader in
measuring protein signaling pathway interactions within the human proteome," said John D.
Rodwell, Ph.D., AxCell's acting President and Chief Technical Officer.
"Now that we have proven the feasibility of our technology," added Dr. Rodwell, "our parent
company, Cytogen, is increasing its investment in AxCell. In the coming months we plan to
expand into new contiguous laboratory space and to add additional equipment, including
robotics, which should allow us to measure protein interactions at even higher rates. We
remain on track to have our InterFunctional Proteomics(TM) database of human protein
interactions at a sufficient size to begin marketing next year."
"We have been able to take advantage of the announced completion of the human genome
project by analyzing these data and identifying putative new ligands," said Dr. Rodwell. "We
are rapidly synthesizing these ligands and plan to use them to fish out never-before-identified
proteins, which we will add to our database and file for intellectual property protection.
Initially, we are working on three important domains in parallel, WW, PDZ, and SH3, which
are associated with a broad spectrum of diseases. We remain on track to completely
characterize at least one domain family by the end of the year."
AxCell Biosciences Corporation has begun a two-to-four year project to develop a
comprehensive, proprietary database of human protein signaling pathways as a tool for
identifying new drug targets. Aberrations in the interactions of proteins with one another are at
the heart of the molecular basis for many diseases. Structural proteomics, or protein
expression, measures the number and types of proteins present in normal and diseased cells.
This approach is useful in defining the structure of proteins in a cell. Some of these proteins
may be targets for drug discovery. However, the role of proteins in disease states remains to
be defined. AxCell's proteomics business is focused upon functional proteomics, the study of
proteins' biological activities. An important function of proteins is the transmission of signals
using intricate pathways populated by proteins which interact with one another. Elucidating the
role proteins play in these signaling pathways allows a better understanding of their function in
cellular behavior and permits identification of potentially novel drug targets. Protein-protein
interactions form the core of the Company's Inter-functional Proteomic Database(TM) (IFP).
AxCell plans to offer the IFP Database to the pharmaceutical industry as a tool to accelerate
the drug discovery process. For additional information on AxCell Biosciences, visit
www.axcellbio.com.
Cytogen Corporation is an established biopharmaceutical company in Princeton, NJ, with two
principal lines of business, proteomics and oncology. The Company is extending its expertise in
antibodies and molecular recognition to the development of new products and a
proteomics-driven drug discovery platform. The Company has established a pipeline of
product candidates based on its proprietary antibody and prostate specific membrane antigen,
or PSMA, technologies. The Company's cancer management franchise currently comprises
three marketed FDA-approved products: ProstaScint(R), used to image the extent and spread
of prostate cancer; OncoScint CR/OV(R), a diagnostic imaging agent for colorectal and
ovarian cancer; and Quadramet(R), for the relief of cancer-related bone pain. The Company's
wholly owned subsidiary, AxCell Biosciences Corporation, is developing a proprietary protein
pathway database as a drug discovery and development tool for the pharmaceutical and
biotechnology industries. For additional information on Cytogen, visit www.cytogen.com.
This news release contains forward-looking statements that involve risks and uncertainties. The
Company's actual results may differ materially from those anticipated in these forward-looking
statements. Factors that may cause such differences include, but are not limited to, those
discussed in Cytogen's Form 10-K Annual Report for the year ended December 31, 1999,
the ability of the Company to develop and maintain high throughput proteomics technology,
and the successful development and market acceptance of its proteomic database. In
particular, we cannot assure you that the protein interaction program will result in the
commercialization of a successful product. We undertake no duty to update these statements.
Source: Cytogen Corporation
Contact:
Richard W. Krawiec, Ph.D., Vice President, Investor Relations
and Corporate Communications, Cytogen Corporation, 609-750-8289, or
publicrelations@cytogen.com
URL: axcellbio.com
cytogen.com .."'
siliconinvestor.com
(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy)
Chuca- Forgive my ATT commerical. But with the POG, who cares! I cares. LOL. |
